These cardiac pharmacology thesis topics cover antihypertensive and antianginal therapy, heart failure medicines, antiarrhythmics, antithrombotic treatment, lipid-lowering therapy and cardiovascular drug safety for MD and DNB Pharmacology candidates. The cardiovascular pharmacology research topics support designs that can be completed within one thesis period using existing cardiology and medicine clinics, prescribing records and routinely available investigations, provided recruitment and follow-up are confirmed. Define the cardiac diagnosis, treatment exposure and primary outcome before preparing the cardiac pharmacology protocol and university-format cardiac pharmacology synopsis.
Last reviewed and updated: September 2026 · 2026–27 admissions
Antihypertensive pharmacotherapy
Drug utilisation pattern of antihypertensive medicines among adults with primary hypertension attending a tertiary care medicine outpatient department: a cross-sectional prescription audit comparing prescribing with standard treatment guidelines and blood pressure control at the index visit.
Comparative prescribing of amlodipine, telmisartan, losartan and enalapril among adults with uncomplicated hypertension: a cross-sectional drug utilisation study assessing prescription frequency, generic use and target blood pressure achievement at routine follow-up.
Antihypertensive polypharmacy among adults with uncontrolled hypertension receiving two or more blood pressure lowering medicines: a cross-sectional prescription study assessing regimen patterns, potential drug interactions and blood pressure control at the index consultation.
Adherence to antihypertensive pharmacotherapy among adults with primary hypertension receiving treatment for at least three months: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing blood pressure control at enrolment.
Association between antihypertensive pill burden and medication adherence among adults with hypertension receiving multiple chronic medicines: a cross-sectional correlation study using daily tablet count and eight-item Morisky Medication Adherence Scale scores at routine follow-up.
Association between beliefs about antihypertensive medicines and treatment adherence among adults with primary hypertension: a cross-sectional correlation study using the Beliefs about Medicines Questionnaire and eight-item Morisky Medication Adherence Scale at the index visit.
Frequency and pattern of adverse drug reactions to antihypertensive medicines among adults attending a tertiary care hypertension clinic: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system over six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for antihypertensive adverse drug reactions: a prospective observational agreement study among adult patients.
Severity and preventability of antihypertensive medicine adverse drug reactions among adults receiving routine treatment: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria over six months.
Prevalence of ankle oedema among adults receiving amlodipine for primary hypertension: a cross-sectional study comparing amlodipine monotherapy with amlodipine-containing combination therapy and assessing symptom severity at the index visit.
Association between angiotensin converting enzyme inhibitor therapy and persistent dry cough among adults with hypertension: a cross-sectional comparative study of enalapril users and angiotensin receptor blocker users assessing cough frequency at enrolment.
Potential drug-drug interactions among adults receiving antihypertensive medicines with treatment for diabetes or dyslipidaemia: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity at the index consultation.
Generic versus brand-name prescribing of antihypertensive medicines among adults with hypertension: a cross-sectional prescription audit comparing prescribing with National Medical Commission guidance and calculating medicine cost per prescription over twelve months.
Concordance of antihypertensive prescribing with the National List of Essential Medicines among adults treated for hypertension: a retrospective prescription audit assessing essential-medicine use, generic prescribing and blood pressure documentation over twelve months.
Fixed dose combination use among adults with hypertension attending a tertiary care outpatient department: a cross-sectional prescription audit assessing component medicines, indication and concordance with standard treatment guidelines at the index visit.
Cost variation among commonly prescribed Indian brands of amlodipine, telmisartan, losartan, enalapril and hydrochlorothiazide: a cross-sectional pharmacoeconomic study using published drug price sources and percentage cost variation for equivalent strengths.
Medication errors in antihypertensive discharge prescriptions among adult medicine inpatients: a retrospective record-based study comparing discharge prescriptions with final medication charts and assessing omission, duplication, dose and frequency errors at discharge.
Antihypertensive prescribing among adults aged sixty-five years or older: a cross-sectional prescription audit using the American Geriatrics Society Beers Criteria and assessing potentially inappropriate medicine use and blood pressure at the index visit.
Availability and stock-out patterns of antihypertensive medicines listed in the National List of Essential Medicines at a government hospital pharmacy: a retrospective register study assessing monthly availability and substitution over twelve months.
Association between government-pharmacy antihypertensive medicine stock-outs and treatment adherence among adults with hypertension: a retrospective and cross-sectional study linking pharmacy availability with patient adherence and blood pressure control during the same period.
Antiplatelet, antianginal and lipid-lowering pharmacotherapy
Drug utilisation pattern of antiplatelet, antianginal and lipid-lowering medicines among adults with stable coronary artery disease: a cross-sectional prescription audit comparing treatment with standard guidelines and documenting angina symptoms at the index visit.
Prescribing patterns of aspirin, clopidogrel and dual antiplatelet therapy among adults with established coronary artery disease: a cross-sectional study assessing indication, treatment duration and concordance with standard treatment guidelines at routine follow-up.
Adherence to antiplatelet therapy among adults with coronary artery disease receiving aspirin, clopidogrel or both: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing treatment continuation at the index visit.
Frequency and pattern of adverse drug reactions to antiplatelet medicines among adults with coronary artery disease: a prospective observational study assessing causality, severity and preventability during six months of routine follow-up.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for antiplatelet-related adverse drug reactions: a prospective observational agreement study.
Self-reported bleeding symptoms among adults receiving dual antiplatelet therapy after acute coronary syndrome: a cross-sectional comparative study assessing aspirin plus clopidogrel exposure and bleeding events during the preceding three months.
Potential drug-drug interactions among adults receiving clopidogrel with proton pump inhibitors and other cardiovascular medicines: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity at the index visit.
Drug utilisation pattern of statins among adults with coronary artery disease or high cardiovascular risk: a cross-sectional prescription audit comparing atorvastatin and rosuvastatin prescribing with standard lipid-management guidelines at the index consultation.
Adherence to statin therapy among adults with dyslipidaemia or coronary artery disease: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing routinely documented lipid values within the preceding three months.
Association between statin adherence and lipid control among adults receiving atorvastatin or rosuvastatin for at least three months: a cross-sectional correlation study using adherence scores and routinely measured low-density lipoprotein cholesterol.
Frequency of statin-associated muscle symptoms among adults receiving atorvastatin or rosuvastatin: a cross-sectional comparative study using structured symptom assessment and documenting treatment duration and routinely ordered creatine kinase measurements where available.
Comparative adverse drug reaction profiles of atorvastatin and rosuvastatin among adults with dyslipidaemia: a prospective observational study using structured adverse-effect assessment and World Health Organization Uppsala Monitoring Centre causality categories over three months.
Generic versus brand-name prescribing of statins and antiplatelet medicines among adults with coronary artery disease: a cross-sectional audit comparing practice with National Medical Commission guidance and calculating medicine cost per prescription.
Cost variation among Indian brands of aspirin, clopidogrel, atorvastatin, rosuvastatin, isosorbide mononitrate and ranolazine: a cross-sectional pharmacoeconomic study using published drug price sources and percentage cost variation.
Fixed dose cardiovascular combination use among adults with coronary artery disease: a cross-sectional prescription audit assessing antiplatelet, statin and antihypertensive components, documented indications and concordance with the National List of Essential Medicines.
Prescribing patterns of nitrates, beta adrenergic receptor blockers and ranolazine among adults with stable angina: a cross-sectional drug utilisation study assessing medicine selection, combination therapy and self-reported angina frequency at the index visit.
Association between nitrate therapy and self-reported headache among adults with stable angina: a cross-sectional comparative study of nitrate users and non-users assessing headache frequency and treatment discontinuation at routine follow-up.
Medication errors involving antiplatelet, statin and antianginal medicines in cardiology discharge prescriptions: a retrospective record-based study comparing discharge orders with inpatient medication charts and assessing errors at discharge.
Concordance of secondary prevention pharmacotherapy with standard treatment guidelines among adults discharged after acute coronary syndrome: a retrospective record audit assessing prescribed antiplatelets, statins, beta adrenergic receptor blockers and renin-angiotensin system medicines at discharge.
Availability and stock-out patterns of antiplatelet, antianginal and lipid-lowering medicines in a government teaching hospital pharmacy: a retrospective register study assessing monthly availability and prescription substitution over twelve months.
Heart failure pharmacotherapy
Drug utilisation pattern of medicines used in adults with chronic heart failure attending a tertiary care cardiology clinic: a cross-sectional prescription audit comparing therapy with standard heart failure guidelines and documenting functional status at enrolment.
Prescribing of renin-angiotensin system inhibitors, beta adrenergic receptor blockers, mineralocorticoid receptor antagonists and diuretics among adults with heart failure: a cross-sectional study assessing guideline-concordant pharmacotherapy at the index visit.
Polypharmacy among adults with chronic heart failure receiving five or more medicines: a cross-sectional prescription study assessing cardiovascular and non-cardiovascular medicines, potential interactions and daily pill burden at routine follow-up.
Adherence to heart failure pharmacotherapy among adults receiving treatment for at least three months: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing functional status at the index consultation.
Association between medication adherence and recent hospitalisation among adults with chronic heart failure: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and documenting heart failure admissions during the preceding six months.
Association between daily pill burden and adherence among adults with chronic heart failure: a cross-sectional correlation study measuring total daily tablets and eight-item Morisky Medication Adherence Scale scores at routine follow-up.
Frequency and pattern of adverse drug reactions to heart failure medicines among adults attending cardiology services: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for heart failure medicine adverse reactions: a prospective observational agreement study.
Severity and preventability of adverse drug reactions associated with heart failure pharmacotherapy: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria during six months.
Potential drug-drug interactions among adults receiving multidrug therapy for chronic heart failure: a cross-sectional prescription study using a recognised interaction reference and categorising clinically important interactions at the index visit.
Association between loop diuretic therapy and routinely documented electrolyte abnormalities among adults with heart failure: a retrospective record-based study comparing furosemide exposure with serum sodium and potassium results within three months.
Association between mineralocorticoid receptor antagonist therapy and hyperkalaemia among adults with heart failure: a retrospective study comparing spironolactone users and non-users using routinely ordered serum potassium measurements within three months.
Monitoring practices among adults receiving spironolactone for chronic heart failure: a retrospective record audit assessing documentation of serum potassium and renal function against standard monitoring recommendations during the first three months.
Monitoring practices among adults receiving renin-angiotensin system inhibitors for heart failure: a retrospective record audit assessing renal function, serum potassium and blood pressure documentation during the first three months of therapy.
Prescribing patterns of digoxin among adults with heart failure or atrial fibrillation: a cross-sectional prescription audit assessing indication, dose, renal function consideration and concurrent interacting medicines at the index visit.
Adverse drug reactions associated with digoxin among adults receiving routine cardiac care: a prospective observational study assessing gastrointestinal, neurological and rhythm-related symptoms and causality during three months of follow-up.
Generic versus brand-name prescribing of heart failure medicines among adults attending a tertiary care cardiology clinic: a cross-sectional audit comparing practice with National Medical Commission guidance and calculating medicine cost per prescription.
Cost variation among Indian brands of carvedilol, metoprolol, ramipril, enalapril, spironolactone and furosemide: a cross-sectional pharmacoeconomic study using published drug price sources and percentage cost variation.
Concordance of heart failure prescribing with the National List of Essential Medicines and standard treatment guidelines: a retrospective prescription audit assessing essential-medicine use and guideline-concordant therapy at discharge over twelve months.
Availability and stock-out patterns of medicines commonly prescribed for chronic heart failure at a government teaching hospital pharmacy: a retrospective register study assessing monthly availability and prescription substitution over twelve months.
Anticoagulant and antiarrhythmic pharmacotherapy
Drug utilisation pattern of oral anticoagulants among adults with atrial fibrillation attending a tertiary care cardiology clinic: a cross-sectional prescription audit assessing medicine selection, indication and concordance with standard treatment guidelines at the index visit.
Prescribing patterns of warfarin, apixaban, rivaroxaban and dabigatran among adults with non-valvular atrial fibrillation: a cross-sectional comparative study assessing patient characteristics, concurrent medicines and bleeding history at enrolment.
Adherence to oral anticoagulant therapy among adults with atrial fibrillation receiving treatment for at least three months: a cross-sectional study using the eight-item Morisky Medication Adherence Scale and assessing missed doses during the preceding month.
Association between anticoagulant pill burden and medication adherence among adults with atrial fibrillation receiving multiple cardiovascular medicines: a cross-sectional correlation study using daily tablet count and eight-item Morisky Medication Adherence Scale scores.
Frequency and pattern of adverse drug reactions to oral anticoagulants among adults with atrial fibrillation: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system during six months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for oral anticoagulant adverse reactions: a prospective observational agreement study.
Severity and preventability of anticoagulant-related adverse drug reactions among adults receiving routine cardiac care: a prospective observational study using the Hartwig severity assessment scale and Schumock and Thornton preventability criteria.
Self-reported bleeding events among adults receiving warfarin compared with direct oral anticoagulants for atrial fibrillation: a comparative cross-sectional study assessing bleeding during the preceding three months and concurrent antiplatelet use.
Monitoring practices among adults receiving warfarin for atrial fibrillation or valvular heart disease: a retrospective record audit assessing international normalized ratio testing frequency and dose documentation during the preceding three months.
Time in therapeutic range among adults receiving warfarin for atrial fibrillation: a retrospective record-based study using routinely available international normalized ratio values and assessing association with documented bleeding or thromboembolic events over six months.
Potential drug-drug interactions among adults receiving warfarin with cardiovascular, antimicrobial or analgesic medicines: a cross-sectional prescription study using a recognised interaction reference and categorising interaction severity at the index consultation.
Potential drug-drug interactions among adults receiving direct oral anticoagulants with cardiovascular medicines: a cross-sectional prescription study using a recognised interaction reference and assessing interaction severity at the index visit.
Patient knowledge regarding warfarin precautions, diet and interaction risks among adults receiving long-term therapy: a cross-sectional interview study using a structured questionnaire and comparing knowledge with counselling documented in clinical records.
Generic versus brand-name prescribing of oral anticoagulants among adults with atrial fibrillation: a cross-sectional audit comparing practice with National Medical Commission guidance and calculating medicine cost per prescription at the index visit.
Cost variation among Indian brands of warfarin, apixaban, rivaroxaban and dabigatran: a cross-sectional pharmacoeconomic study using published drug price sources and calculating percentage cost variation for equivalent strengths.
Drug utilisation pattern of antiarrhythmic medicines among adults attending cardiology services for documented rhythm disorders: a cross-sectional prescription audit assessing amiodarone, beta adrenergic receptor blockers and other agents at the index visit.
Monitoring practices among adults receiving long-term amiodarone therapy: a retrospective record audit assessing thyroid, liver, pulmonary and electrocardiographic monitoring against standard recommendations during the preceding six months.
Frequency of adverse drug reactions among adults receiving amiodarone for atrial or ventricular arrhythmias: a prospective observational study assessing causality, severity and treatment continuation during six months of routine follow-up.
Medication errors involving anticoagulant and antiarrhythmic medicines in cardiology discharge prescriptions: a retrospective record-based study comparing discharge prescriptions with inpatient medication charts and assessing dosing, duplication and omission errors.
Availability and stock-out patterns of anticoagulant and antiarrhythmic medicines at a government teaching hospital pharmacy: a retrospective register study assessing monthly availability and prescription substitution over twelve months.
Cardiovascular pharmacovigilance, rational prescribing and medication safety
Overall cardiovascular drug utilisation among adult medicine and cardiology outpatients at a tertiary care teaching hospital: a cross-sectional prescription audit using World Health Organization prescribing indicators and the National List of Essential Medicines over twelve months.
Cardiovascular polypharmacy among adults aged sixty-five years or older attending medicine and cardiology clinics: a cross-sectional prescription study assessing medicine count, potentially inappropriate medicines and potential drug interactions at the index visit.
Potentially inappropriate cardiovascular medicine use among adults aged sixty-five years or older: a cross-sectional prescription audit using the American Geriatrics Society Beers Criteria and assessing prevalence at the index consultation.
Potential drug-drug interactions among adults receiving five or more cardiovascular and non-cardiovascular medicines: a cross-sectional prescription study using a recognised interaction reference and categorising interaction frequency and severity at the index visit.
Frequency and pattern of adverse drug reactions to cardiovascular medicines reported from medicine and cardiology departments: a prospective observational study using the World Health Organization Uppsala Monitoring Centre causality assessment system over twelve months.
Comparison of the Naranjo Adverse Drug Reaction Probability Scale with the World Health Organization Uppsala Monitoring Centre causality assessment system for cardiovascular adverse drug reactions: a prospective observational agreement study.
Inter-observer agreement in causality assessment of cardiovascular adverse drug reactions using the World Health Organization Uppsala Monitoring Centre causality assessment system: a prospective study comparing two independent trained assessors during twelve months.
Inter-observer agreement in severity assessment of cardiovascular adverse drug reactions using the Hartwig severity assessment scale: a prospective observational study comparing two independent trained assessors among reported reactions during twelve months.
Inter-observer agreement in preventability assessment of cardiovascular adverse drug reactions using Schumock and Thornton preventability criteria: a prospective observational study comparing two independent trained assessors over twelve months.
Completeness of cardiovascular adverse drug reaction reporting forms submitted to a tertiary hospital monitoring centre: a retrospective record-based study comparing completed fields with Pharmacovigilance Programme of India reporting requirements over two years.
Knowledge, attitude and practice regarding cardiovascular adverse drug reaction reporting among doctors, nurses and pharmacists: a cross-sectional questionnaire study using a validated pharmacovigilance instrument and assessing reporting experience during the preceding year.
Effect of a single structured pharmacovigilance teaching session on knowledge of cardiovascular adverse drug reaction reporting among postgraduate residents: a before-and-after study using the same validated questionnaire immediately before and after teaching.
Barriers to adverse drug reaction reporting among prescribers managing cardiovascular diseases in a teaching hospital: a cross-sectional questionnaire study using a validated instrument and assessing previous reporting behaviour during the preceding twelve months.
Generic prescribing of cardiovascular medicines in medicine and cardiology outpatient departments: a cross-sectional prescription audit comparing observed practice with National Medical Commission guidance and the National List of Essential Medicines over twelve months.
Prescription completeness and legibility for cardiovascular medicines in a tertiary care outpatient department: a cross-sectional audit against World Health Organization good-prescribing principles assessing medicine, dose, frequency, duration and prescriber information.
Medication errors in cardiovascular discharge prescriptions among adult inpatients: a retrospective record-based study comparing discharge prescriptions with final medication charts and assessing omission, duplication, dose, frequency and duration errors at discharge.
Fixed dose cardiovascular combination prescribing among adult outpatients: a cross-sectional prescription audit assessing formulation components, documented indication and concordance with the National List of Essential Medicines and standard treatment guidelines.
Quality of cardiovascular drug promotional literature distributed to prescribers in a teaching hospital: a cross-sectional content analysis comparing promotional claims and references with World Health Organization ethical criteria for medicinal drug promotion.
Completeness and readability of package inserts supplied with commonly prescribed cardiovascular medicines in India: a cross-sectional content analysis comparing safety, interaction and dosing information with applicable Indian regulatory requirements.
Association between cardiovascular medicine stock-outs and prescription substitution at a government teaching hospital: a retrospective study linking pharmacy availability records with anonymised outpatient prescriptions and assessing substitution frequency over twelve months.
Not the pharmacology subspeciality you need? Cardiac pharmacology is one section of our full pharmacology collection — the hub page lists every subspeciality, each with its own free topic list. Updated September 2026.
📌 Updated for 2026–2027 MD Pharmacology admissions: Cardiac Pharmacology
The accompanying research guidance has been reviewed for treatment-selection bias, dose titration, cardiac outcome measurement and feasible safety follow-up.
Many projects can use standardised blood-pressure measurements, ECGs, prescriptions, creatinine, electrolytes and lipid profiles; heart failure projects may also need routinely recorded echocardiography.
Drug assays, platelet-function testing, genotyping, ambulatory ECG monitoring and advanced imaging are not prerequisites for every topic; select projects needing these facilities only after confirming access and cost.
Publication potential lies in well-defined local prescribing gaps, treatment persistence, tolerability and avoidable harm, supported by appropriate denominators and credible comparison groups.
Generate a protocol from any topic above
Select Generate Protocol → beside any title in the list above and receive a submission-ready document built around that topic, containing all eighteen components:
Introduction / Synopsis
Research Question
Aim of the Study
Primary Objective
Secondary Objectives
Materials and Methods
Inclusion Criteria
Exclusion Criteria
Sample Size Calculation
Methodology
Statistical Analysis
Ethical Considerations
Review of Literature
References
Gantt Chart / Study Timeline
Patient Information Sheet
Consent Form
Data Collection Form
Already have your thesis title?
Generate the full cardiac pharmacology protocol directly — objectives, methodology, sample size, statistics, timeline, references and annexures.
Alongside cardiac pharmacology protocols and synopses, support is also available for departmental presentations, journal club presentations, ethics committee presentations, and posters and oral presentations for medical conferences — for postgraduate residents, board trainees and research scholars across India and the GCC. Prepared by a practising doctor with long experience in medical publishing and thesis supervision.
The topics above work as research questions anywhere — what changes is the document the institution expects, and who approves it before data collection begins. The Gulf equivalent of an Indian synopsis is the cardiac pharmacology research proposal submitted to an institutional review board, and it ordinarily carries three sections an Indian synopsis does not: a Gantt chart, a budget and resources section, and a Declaration of Helsinki statement.
Board and residency programmes — country by country
Saudi Arabia — SCFHS and the Saudi Board. Residency and fellowship training under the Saudi Commission for Health Specialties includes a research project with a set timeline, and the cardiac pharmacology research proposal is the document prepared at the outset and cleared by the institutional review board before recruitment starts.
United Arab Emirates — DHA, DOH Abu Dhabi and MOHAP. Residents training in Dubai, Abu Dhabi and the northern emirates prepare a cardiac pharmacology research protocol for their programme and submit it for institutional review board approval before any data are collected.
Qatar — DHP (formerly QCHP) and Hamad Medical Corporation. A cardiac pharmacology IRB proposal is reviewed before recruitment, with the ethics section written to the institution's own template rather than a generic one.
Bahrain — NHRA. Trainees turning cardiac pharmacology research topics into a project need the proposal cleared by their institutional research and ethics committee before fieldwork begins.
Oman — OMSB. Residency programmes under the Oman Medical Specialty Board include a research component, and the cardiac pharmacology research proposal is the document assessed at the start of it.
Kuwait — KIMS. A cardiac pharmacology study protocol goes to the institutional committee for approval before the project begins.
Arab Board programmes across the region. The Arab Board carries its own research requirement irrespective of the host country, and the cardiac pharmacology proposal follows the same structure throughout.
Postgraduate degrees — Malaysia, the Gulf and beyond
Malaysia — MMed, the National Medical Research Register and MREC. A cardiac pharmacology dissertation proposal for a Master of Medicine programme carried out in a Ministry of Health facility must be registered on the NMRR and approved by the Medical Research and Ethics Committee before the study begins, and the guidance asks for submission four to six months ahead of data collection. Every investigator on the study team registers on the NMRR as well, so the methodology, ethics and team sections are written in far more detail than an Indian synopsis requires.
PhD and Master's candidates elsewhere. University programmes generally require a full cardiac pharmacology research proposal of roughly 6,000 to 10,000 words, with an extended literature review, a theoretical framework and a detailed methodology chapter.
PhD and MMed proposals are written individually by a medical doctor and revised until the supervisor accepts them. They are not produced by the automated protocol generator.
🔥 Trending research areas in Cardiac Pharmacology for 2026–27
Implementation of heart failure pharmacotherapy: studying initiation, titration and persistence can identify whether affordability, low blood pressure, renal function or other documented factors limit treatment in eligible patients.
Cardiorenal treatment safety: longitudinal creatinine and potassium measurements can help describe treatment tolerance, provided sampling is anchored to initiation and dose changes rather than pooled across unrelated visits.
Personalised antithrombotic treatment: renal dose appropriateness, concomitant antiplatelets, treatment interruption and bleeding are practical research questions because exposure and risk change during follow-up.
Digital medication and ECG review: evaluating interaction alerts, QTc screening or adherence tools against a prespecified clinical reference can establish local usefulness while measuring false alarms and missed cases.
Protocol and synopsis guidance
What a Cardiac Pharmacology protocol must contain
Define the cardiac population. Specify the indication, diagnostic criteria, clinical stability and relevant disease subtype. For heart failure, name the ejection-fraction classification and measurement method; for coronary disease, separate acute presentations from stable disease. Record baseline blood pressure, heart rate, renal function, potassium, comorbidities and background treatment.
Define exposure over time. Record the generic drug, formulation, starting dose, titration, achieved dose, switching, interruptions and adherence. Align eligibility, treatment initiation and the start of follow-up. Classifying patients by a dose reached months later while counting outcomes from their first visit can introduce immortal-time bias. Patients who tolerate titration also differ from those who stop because of hypotension, renal dysfunction or clinical deterioration.
Make endpoints reproducible. Prespecify blood-pressure technique and timing, ECG acquisition and QT correction, laboratory windows and clinical-event definitions. Use a named bleeding classification appropriate to the population. Record hospitalisations and deaths separately from surrogate changes such as LDL cholesterol, QTc or ejection fraction. Include an escalation route for bleeding, symptomatic hypotension, bradyarrhythmia and important electrolyte abnormalities.
Cardiac Pharmacology synopsis versus Cardiac Pharmacology protocol
The synopsis summarises the question, rationale and proposed methods in the university format. The protocol provides the operational rules for recruitment, treatment recording, follow-up, outcome assessment and analysis. Some institutions use the terms interchangeably, but both documents should agree on the study population, primary endpoint and exposure definition.
For cardiac drug studies, the protocol must explain what happens when the treating clinician changes diuretics, adds another medicine, reduces a dose or interrupts anticoagulation. Specify whether the analysis follows initial treatment or actual exposure over time, how acute admissions are handled and when renal function and electrolytes are measured. In an observational study, treatment decisions remain with the treating team; investigator-assigned treatment requires an appropriate interventional design and approval pathway.
Sample size and statistical analysis
Choose a realistic primary endpoint. Calculate sample size from the expected proportion and precision for a prescribing audit, or the clinically meaningful between-group difference and variability for blood pressure or another continuous outcome. A study powered for a laboratory change is not automatically powered for mortality, major bleeding or rare arrhythmias. Allow for incomplete follow-up and unusable ECG or laboratory measurements.
Analyse change and repeated visits correctly. For treatment comparisons, consider baseline-adjusted models rather than relying only on within-group significance tests. Repeated blood pressures, ECGs and admissions from one patient are correlated observations. Use suitable longitudinal or event-based methods and report effect estimates with confidence intervals. Describe missing observations, withdrawals and deaths explicitly.
Control clinically relevant confounding. Prespecify disease severity, ejection fraction where relevant, renal function, blood pressure, age, comorbidity and background treatment. Limit model complexity to the available sample and event count. Propensity methods address measured differences only. For composite endpoints, define each component and report its frequency; a result driven by minor events cannot be presented as a mortality benefit.
1. How do I choose a feasible Cardiac Pharmacology thesis topic?
For 2026–2027 admissions, choose a common cardiac indication with enough eligible patients and an outcome measurable during the available follow-up. Check cardiology or medicine collaboration, prescription access, ECG availability and routine laboratory schedules. Select one primary question, such as dose appropriateness, adherence, blood-pressure response or treatment-emergent laboratory abnormalities, rather than combining several unrelated drug classes and outcomes.
2. Which study designs are suitable for cardiac drug research?
Depending on university requirements, suitable options include cross-sectional prescribing or adherence studies, retrospective cohort studies, prospective observational cohorts, case-control studies of defined outcomes, pharmacoeconomic evaluations and appropriately approved interventional trials. A prescription audit describes practice but cannot establish comparative treatment effectiveness. A single-arm before-and-after study remains vulnerable to regression to the mean, concurrent treatment changes and recovery from an acute illness.
3. What should I agree with my guide before finalising the topic?
Agree on the indication, clinical setting, primary outcome, comparator, recruitment target and follow-up duration. Specify the ejection-fraction subgroup if relevant, treatment initiation date, dose recording, background therapy and adherence measure. Confirm access to ECGs, renal function, electrolytes and clinical-event records. Assign responsibility for outcome adjudication, urgent safety findings, missing follow-up, statistical analysis and funding.
4. Can I study QT prolongation using routine ECGs?
Yes, if ECG quality and timing support the research question. Prespecify the lead selection, measurement method, heart-rate correction formula and handling of atrial fibrillation, paced rhythms and wide QRS complexes. Record baseline QTc, heart rate, potassium, magnesium where available, co-prescribed QT-prolonging drugs and the interval from dosing to ECG. Unchecked automated QTc readings and inconsistent correction formulae can distort comparisons. QTc prolongation is a safety marker; it is not the same endpoint as documented torsades de pointes or sudden cardiac death.
5. How does a Cardiac Pharmacology synopsis differ from a protocol?
The synopsis is the proposal submitted in the required university format, while the protocol specifies how the study will be conducted. Both must use the same cardiac diagnosis, exposure definition, comparator and primary outcome. The protocol additionally needs rules for titration, co-medication, treatment interruption, repeated measurements, safety escalation and incomplete follow-up. Follow local terminology and submission requirements.
6. What ethics safeguards are needed for cardiac pharmacology studies?
Obtain Institutional Ethics Committee approval before recruitment or research access to identifiable records. A retrospective review needs an approved consent waiver where applicable; it is not automatically exempt. Obtain informed consent for prospective participation. If children are included, obtain parental or legal guardian consent and age-appropriate assent from about seven years. Seek separate consent for identifiable photographs or video.
Routine-care observational studies should add no radiation, contrast or research-only venepuncture. If additional ECGs, imaging or blood sampling are essential, disclose and justify them separately. For additional blood sampling, state numerical limits in mL per draw and cumulatively, with weight-based limits for children, for ethics review. Protect prescription, ECG and laboratory identifiers through coding and restricted access.
Name the treating cardiologist or physician as the first contact for newly detected arrhythmia, important QTc prolongation, severe electrolyte abnormalities, renal deterioration or bleeding. Specify immediate emergency escalation for unstable patients and the institutional adverse drug reaction reporting route. Observational research must not delay care or direct withdrawal of indicated treatment; investigator-assigned treatment requires the applicable trial permissions and safety provisions.
7. Can better outcomes in patients receiving higher heart failure drug doses prove a dose benefit?
No. Patients able to tolerate higher doses may have better blood pressure, renal function, clinical stability and adherence at baseline. Patients receiving low doses may have hypotension, advanced disease or early adverse effects. This treatment-selection process can create an apparent benefit even when dose is not its sole cause.
Define a common eligible population and time origin, document reasons for dose limitation, and measure disease severity and background therapy. Do not use a future achieved dose to classify exposure retrospectively from baseline: patients must survive and remain observed long enough to reach it. Prespecify an appropriate time-varying exposure or justified landmark approach with statistical support. Adjust for measured confounding and describe any remaining association without claiming that an observational comparison proves causation.
8. Can these topics support PhD proposals and Gulf board research projects?
Yes, after adapting the scope and methods to the qualification. An MD synopsis generally supports a bounded supervised dissertation; a PhD proposal requires a stronger original contribution and a coherent programme of research. Confirm access to cardiac services, prescribing data, local formularies and follow-up before transferring a topic to another setting.
For SCFHS and Saudi Board training, the Arab Board of Health Specializations, and DHP, DHA, DOH or MOHAP-linked programmes, check the exact specialty curriculum and training institution. Where a mandatory board research project applies, confirm supervision, local ethics approval, required format and assessment deadlines. Research requirements are programme-specific and should not be inferred solely from the name of a licensing authority.
9. When should I register my Cardiac Pharmacology thesis or study?
Confirm feasibility and supervisor agreement early, then submit the title and synopsis within the university or board deadline. Obtain ethics approval and any applicable regulatory permissions before starting research activities. Complete required prospective trial registration before the first participant is enrolled; for Indian studies, establish the applicable Clinical Trials Registry-India requirements with the ethics committee. University registration, ethics approval and trial registration are separate processes.
Found a topic that fits your department?
Generate its full protocol — objectives, methodology, sample size, statistics, timeline, references and annexures — in editable format.
